RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS RAGE IN THE SERUM OF BONE TUMORS PATIENTS

Download full text PDF
Issue: 
4
Year: 
2017

I.V. Babkina
Dr.Sc. (Med.), Professor, Laboratory of Clinical Biochemistry, N.N. Blokhin Russian Cancer Research Center (Moscow)
E-mail: biochimia@yandex.ru
Y.S. Timofeev
Ph.D. (Med.), Assistant, Department of Clinical Biochemistry and Laboratory Diagnostics,
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Yu.N. Soloviev
Dr.Sc. (Med.), Professor, Academician of the Russian Academy of Sciences, Chief Research Scientist,
Department of Pathological Anatomy, N.N. Blokhin Russian Cancer Research Center (Moscow)
I.V. Bulycheva
Dr.Sc. (Med.), Surgical Pathologist, N.N. Blokhin Russian Cancer Research Center (Moscow)
M.D. Aliyev
Dr.Sc. (Med.), Professor, Academician of the Russian Academy of Sciences,
Head of Department General Oncology, N.N. Blokhin Russian Cancer Research Center (Moscow)
N.E. Kushlinskii
Dr.Sc. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences,
Head of Clinical Biochemistry Laboratory, N.N. Blokhin Russian Cancer Research Center (Moscow)

extracellular proteins and leads to changes in metabolic processes. One of the AGEs receptors − RAGE (receptor for advanced glycation end products) − transmembrane protein type 1 immunoglobulin family. The experimental studies have shown that extracellular AGE can directly regulate the growth and development of rats osteosarcoma cells. The results of clinical studies RAGE in patients with bone tumors in the available literature are absent. Aim. To compare baseline serum RAGE in patients with malignant, borderline and benign bone tumors. Material and methods. Serum RAGE levels was compared in 115 patients with primary bone tumors (malignant − 63 (osteosarcoma − 18, chondrosarcoma − 38, Ewing's sarcoma – 4, undifferentiated pleomorphic sarcoma − 1, chordoma − 2) borderline (giant cell tumor of bone ) − 26; benign tumors and tumor −like lesions of bone − 26) and 40 healthy age −matched people. RAGE concentration was determined by ELISA reagents («R&D» (SA) in patients before the start of a specific treatment. Results. In the blood serum of healthy people the average content of RAGE was 1632.4 ± 105.7 pg/ml and was significantly higher than that of patients with malignant 1315.9 ± 85.1 pg/ml (p < 0.05) and borderline tumors of bone 1285.8 ± 115.2 pg/ml (p < 0.05). In benign bone tumors RAGE average was equal to 1513.6 ± 107.9 pg/ml, significant differences are marked only by comparison with patients with malignant bone tumors (p < 0.05). RAGE serum levels in osteosarcoma was significantly higher than in chondrosarcoma (p < 0.05). In poorly differentiated bone tumors serum RAGE were significantly higher than in high −grade (p < 0.05), in patients with lesions of long bones − significantly higher than the flat bone lesions (p < 0.05). There were no significant differences in the serum RAGE levels in patients and healthy people control group by sex. In patients with bone tumors observed an inverse relationship between age and serum RAGE levels (r = −0,4; p < 0,001). Conclusion. These findings suggest that differences in the RAGE expression in patients with bone tumors compared to healthy individuals of appropriate age may be linked to pathogenic changes associated with the growth of bone sarcomas. Determination of RAGE may be the subject of further research into its role in the prognosis of malignant bone tumors.

Keywords: 
RAGE
serum
bone tumors.

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.